keyword
MENU ▼
Read by QxMD icon Read
search

Nsabp cancer

keyword
https://www.readbyqxmd.com/read/29128898/21-gene-recurrence-score-for-prognosis-and-prediction-of-taxane-benefit-after-adjuvant-chemotherapy-plus-endocrine-therapy-results-from-nsabp-b-28-nrg-oncology
#1
Eleftherios P Mamounas, Gong Tang, Soonmyung Paik, Frederick L Baehner, Qing Liu, Jong-Hyeon Jeong, S Rim Kim, Steven M Butler, Farid Jamshidian, Diana B Cherbavaz, Amy P Sing, Steven Shak, Thomas B Julian, Barry C Lembersky, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
BACKGROUND: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen. METHODS: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients...
November 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29072977/long-term-follow-up-of-cardiac-function-and-quality-of-life-for-patients-in-nsabp-protocol-b-31-nrg-oncology-a-randomized-trial-comparing-the-safety-and-efficacy-of-doxorubicin-and-cyclophosphamide-ac-followed-by-paclitaxel-with-ac-followed-by-paclitaxel-and
#2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, Priya Rastogi, Charles E Geyer, Sandra M Swain, Jong-Hyeon Jeong, Louis Fehrenbacher, Howard M Gross, Adam M Brufsky, Patrick J Flynn, Tanya A Wahl, Thomas E Seay, James L Wade, David D Biggs, James N Atkins, Jonathan Polikoff, John L Zapas, Eleftherios P Mamounas, Norman Wolmark
Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer...
October 26, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28968398/snps-near-the-cysteine-proteinase-cathepsin-o-gene-ctso-determine-tamoxifen-sensitivity-in-er%C3%AE-positive-breast-cancer-through-regulation-of-brca1
#3
Junmei Cairns, James N Ingle, Lawrence D Wickerham, Richard Weinshilboum, Mohan Liu, Liewei Wang
Tamoxifen is one of the most commonly employed endocrine therapies for patients with estrogen receptor α (ERα)-positive breast cancer. Unfortunately the clinical benefit is limited due to intrinsic and acquired drug resistance. We previously reported a genome-wide association study that identified common SNPs near the CTSO gene and in ZNF423 associated with development of breast cancer during tamoxifen therapy in the NSABP P-1 and P-2 breast cancer prevention trials. Here, we have investigated their roles in ERα-positive breast cancer growth and tamoxifen response, focusing on the mechanism of CTSO...
October 2017: PLoS Genetics
https://www.readbyqxmd.com/read/28954297/long-term-peripheral-neuropathy-in-breast-cancer-patients-treated-with-adjuvant-chemotherapy-nrg-oncology-nsabp-b-30
#4
RANDOMIZED CONTROLLED TRIAL
Hanna Bandos, Joy Melnikow, Donna R Rivera, Sandra M Swain, Keren Sturtz, Louis Fehrenbacher, James L Wade, Adam M Brufsky, Thomas B Julian, Richard G Margolese, Edward C McCarron, Patricia A Ganz
Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28856246/breast-cancer-chemoprevention-pharmacogenomics-deep-sequencing-and-functional-genomics-of-the-znf423-and-ctso-genes
#5
Duan Liu, Ming-Fen Ho, Daniel J Schaid, Steven E Scherer, Krishna Kalari, Mohan Liu, Joanna Biernacka, Vivien Yee, Jared Evans, Erin Carlson, Matthew P Goetz, Michiaki Kubo, D Lawrence Wickerham, Liewei Wang, James N Ingle, Richard M Weinshilboum
Our previous GWAS using samples from the NSABP P-1 and P-2 selective estrogen receptor modulator (SERM) breast cancer prevention trials identified SNPs in ZNF423 and near CTSO that were associated with breast cancer risk during SERM chemoprevention. We have now performed Next Generation DNA sequencing to identify additional SNPs that might contribute to breast cancer risk and to extend our observation that SNPs located hundreds of bp from estrogen response elements (EREs) can alter estrogen receptor alpha (ERα) binding in a SERM-dependent fashion...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28667456/from-clinical-trials-to-clinical-practice-outcome-of-nsabp-b27-neoadjuvant-chemotherapy-regimen-for-high-risk-early-stage-breast-cancer
#6
Hikmat Abdel-Razeq, Lina Marei, Salwa S Saadeh, Hazem Abdulelah, Mahmoud Abu-Nasser, Mourad Salam, Walid Daana, Basel Al-Haj Ali, Ayat Taqash
PURPOSE: Majority of Jordanian breast cancer patients present at a relatively young age and with locally advanced disease highlight the importance of neoadjuvant chemotherapy. This study evaluated the efficacy and safety of NSABP-B27 regimen in high-risk patients in daily clinical practice. METHODS: Patients' medical records and hospital database were searched for all consecutive patients treated at our institution for breast cancer using neoadjuvant NSABP-B27 chemotherapy regimen...
June 30, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28666922/controversies-in-treatment-selection-for-patients-with-equivocal-er-and-her2-results
#7
Giuseppe Viale
Formally, the term "equivocal" should not be used when reporting results of the assessment of ER status, but controversies exist about the prognostic and predictive value of a low ER expression (i.e. 1-9% positive cells) in breast cancer (so called ER-poor tumors). Because of the rarity of these cases, prospective clinical trials have not been conducted (and are unlikely to be conducted in the future) to define the optimal treatment strategy for the small subset of patients with ER-poor breast cancer. Therefore, the only available data stem from retrospective subgroup analyses of randomized clinical trials or from clinical datasets of individual Institutions...
August 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28661894/exploring-explanatory-models-of-risk-in-breast-cancer-risk-counseling-discussions-nsabp-nrg-oncology-decision-making-project-1
#8
Christine M Gunn, Barbara Bokhour, Victoria A Parker, Patricia A Parker, Sarah Blakeslee, Hanna Bandos, Christine Holmberg
BACKGROUND: Explanatory models represent patient understanding of etiology, pathophysiology, illness, symptoms, and treatments, but little attention has been paid to how they are used by patients "at risk" for future disease. OBJECTIVE: The aims of this study were to elucidate what constitutes an explanatory model of risk and to describe explanatory models of risk related to developing breast cancer. METHODS: Thirty qualitative interviews with women identified as at an increased risk for breast cancer were conducted...
June 28, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28624048/comparison-of-two-different-types-of-oxidized-regenerated-cellulose-for-partial-breast-defects
#9
COMPARATIVE STUDY
Jeeyeon Lee, Jin Hyang Jung, Wan Wook Kim, Jung Dug Yang, Jeong Woo Lee, Junjie Li, Ho Yong Park
BACKGROUND: A defect after partial mastectomy, sometimes, is hard to be filled with patient's own breast tissue. Two different types of oxidized regenerated cellulose (ORC) for filling of partial defects in small-sized breasts were compared with respect to clinicopathologic factors and outcomes. METHODS: A total of 45 patients with breast cancer underwent conventional partial mastectomy with insertion of an ORC filling material. The two filling materials used were a hemostasis-purposed ORC and adhesion barrier-purposed ORC...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28581400/first-results-of-a-phase-2-trial-of-once-weekly-hypofractionated-breast-irradiation-whbi-for-early-stage-breast-cancer
#10
Anthony E Dragun, Nicholas J Ajkay, Elizabeth C Riley, Teresa L Roberts, Jianmin Pan, Shesh N Rai, Dharamvir Jain, Amy R Quillo, Charles R Scoggins, Kelly M McMasters, Shiao Y Woo
PURPOSE: To report early outcome analysis of a prospective institutional phase 2 trial of weekly hypofractionated breast irradiation (WHBI) for patients undergoing breast-conserving surgery (BCS). METHODS AND MATERIALS: Patients who underwent BCS for American Joint Committee on Cancer stage 0, I, or II breast cancer with negative surgical margins received whole-breast radiation therapy to 30 or 28.5 Gy in 5 weekly fractions with or without an additional boost. The eligibility criteria were the same as for NSABP (National Surgical Adjuvant Breast and Bowel Project) B39/RTOG (Radiation Therapy Oncology Group) 0413, and there were no restrictions on age, breast size, tumor grade, receptor status, or the use of cytotoxic chemotherapy for otherwise eligible patients...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28447237/effects-of-metformin-versus-placebo-on-vitamin-b12-metabolism-in-non-diabetic-breast-cancer-patients-in-cctg-ma-32
#11
Ana Elisa Lohmann, Mira F Liebman, William Brien, Wendy R Parulekar, Karen A Gelmon, Lois E Shepherd, Jennifer A Ligibel, Dawn L Hershman, Priya Rastogi, Ingrid A Mayer, Timothy J Hobday, Julie Lemieux, Alastair Mark Thompson, Kathleen I Pritchard, Timothy Joseph Whelan, Som D Mukherjee, Haji I Chalchal, Vanessa Bernstein, Vuk Stambolic, Bingshu E Chen, Pamela Jean Goodwin
BACKGROUND: Metformin is associated with low levels of vitamin B12 (VitB12) in patients with diabetes. The CCTG/MA.32 trial investigates the effects of metformin vs placebo on breast cancer (BC) outcomes in non-diabetic high-risk BC patients. We analyzed VitB12 at baseline and after 6 months of metformin (versus placebo) in the first 492 patients with paired blood samples. METHODS: VitB12 was analyzed centrally in baseline and 6-month fasting plasma. Levels <181 pmol/L were considered deficient, 181-221 pmol/L borderline, and ≥222 pmol/L sufficient...
July 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28398846/anthracyclines-in-early-breast-cancer-the-abc-trials-usor-06-090-nsabp-b-46-i-usor-07132-and-nsabp-b-49-nrg-oncology
#12
RANDOMIZED CONTROLLED TRIAL
Joanne L Blum, Patrick J Flynn, Greg Yothers, Lina Asmar, Charles E Geyer, Samuel A Jacobs, Nicholas J Robert, Judith O Hopkins, Joyce A O'Shaughnessy, Chau T Dang, Henry Leonidas Gómez, Louis Fehrenbacher, Svetislava J Vukelja, Alan P Lyss, Devchand Paul, Adam M Brufsky, Jong-Hyeon Jeong, Linda H Colangelo, Sandra M Swain, Eleftherios P Mamounas, Stephen E Jones, Norman Wolmark
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab...
August 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28285537/milestone-clinical-trials-of-the-national-surgical-adjuvant-breast-and-bowel-project-nsabp
#13
REVIEW
Priya Rastogi, D Lawrence Wickerham, Charles E Geyer, Eleftherios P Mamounas, Thomas B Julian, Norman Wolmark
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized clinical trials evaluating local and systemic therapy. In 2014, the NSABP merged with two other US National Cancer Institute-funded cooperative groups, the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG), to form NRG Oncology. The combined organization has 218 member institutions with more than 600 affiliate centers located throughout the United States, Canada, Puerto Rico, and other international sites...
February 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28094211/likelihood-of-unacceptable-normal-tissue-doses-in-breast-cancer-patients-undergoing-regional-nodal-irradiation-in-routine-clinical-practice
#14
Jose Bazan, Dominic DiCostanzo, Karla Kuhn, Lonika Majithia, Allison Quick, Nilendu Gupta, Julia White
PURPOSE: As indications for regional nodal irradiation (RNI) for breast cancer have expanded, so too has scrutiny over potential late toxicity from radiotherapy. This emphasizes the need for careful radiation treatment planning to maximize the therapeutic ratio. We sought to evaluate how often unacceptable doses (UDs) to organs at risk (OARs) occur and the associated factors for patients receiving RNI in daily practice. METHODS AND MATERIALS: Treatment records of patients who received RNI from February 2012 to May 2015 were studied...
May 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/27864694/the-effect-on-surgical-complications-of-bevacizumab-added-to-neoadjuvant-chemotherapy-for-breast-cancer-nrg-oncology-nsabp-protocol-b-40
#15
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Christine K Zoon, Kelley M Kidwell, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NRG Oncology/NSABP trial B-40 tested the impact of adding bevacizumab (bev) to neoadjuvant chemotherapy for operable breast cancer. Secondary endpoints included rates of surgical complications after surgery in patients who did or did not receive bev. METHODS: A total of 1206 women with HER2-negative operable breast cancer were randomly assigned to receive one of three different docetaxel-plus-anthracycline-based regimens, without or with bev (15 mg/kg every 3 weeks) for the first 6 of 8 cycles and for 10 doses postoperatively...
November 18, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27812689/association-of-polymorphisms-in-fcgr2a-and-fcgr3a-with-degree-of-trastuzumab-benefit-in-the-adjuvant-treatment-of-erbb2-her2-positive-breast-cancer-analysis-of-the-nsabp-b-31-trial
#16
RANDOMIZED CONTROLLED TRIAL
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Jong-Hyeon Jeong, Joseph P Costantino, Norman Wolmark, Soonmyung Paik, Kay L Pogue-Geile
Importance: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects. Objective: To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2-positive breast cancer...
March 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/27730423/assessment-of-pathologic-response-and-long-term-outcome-in-locally-advanced-breast-cancers-after-neoadjuvant-chemotherapy-comparison-of-pathologic-classification-systems
#17
Misun Choi, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Soo Youn Cho, Eun Yoon Cho
PURPOSE: Several pathologic classification systems have been developed to evaluate tumor response after neoadjuvant chemotherapy (NAC) for breast cancer. We aimed to compare pathologic classification systems and to investigate prognostic factors and risk stratification according to molecular subtype in relation to survival. METHODS: We retrospectively evaluated pathologic response after NAC in 485 breast cancer patients by applying the National Surgical Adjuvant Breast and Bowel Project B18 trial (NSABP-B18), Miller and Payne system, Chevallier's classification, Sataloff's classification, residual cancer burden (RCB), residual disease in breast and nodes (RDBN), and clinical-pathologic stage + estrogen receptor status and grade staging system (CPS + EG)...
December 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27693116/epirubicin-with-cyclophosphamide-followed-by-docetaxel-with-trastuzumab-and-bevacizumab-as-neoadjuvant-therapy-for-her2-positive-locally-advanced-breast-cancer-or-as-adjuvant-therapy-for-her2-positive-pathologic-stage-iii-breast-cancer-a-phase-ii-trial-of-the
#18
MULTICENTER STUDY
John W Smith, Marc E Buyse, Priya Rastogi, Charles E Geyer, Samuel A Jacobs, Erica J Patocskai, André Robidoux, Alison K Conlin, Bilal Ansari, George P Keogh, Philip J Stella, Howard M Gross, Raymond S Lord, Jonathan A Polikoff, Celine Mauquoi, Eleftherios P Mamounas, Sandra M Swain, Norman Wolmark
BACKGROUND: The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC) or pathologic stage 3 breast cancer (PS3BC). PATIENTS AND METHODS: Patients received every 3 week treatment with 4 cycles of EC (90/600 mg/m(2)) followed by 4 cycles of docetaxel (100 mg/m(2)). Targeted therapy with standard-dose trastuzumab with bevacizumab 15 mg/kg was given for a total of 1 year...
February 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27562475/quality-of-life-and-symptoms-in-long-term-survivors-of-colorectal-cancer-results-from-nsabp-protocol-lts-01
#19
Hiroko Kunitake, Marcia M Russell, Ping Zheng, Greg Yothers, Stephanie R Land, Laura Petersen, Louis Fehrenbacher, Jeffery K Giguere, D Lawrence Wickerham, Clifford Y Ko, Patricia A Ganz
PURPOSE: Little is known about health-related quality of life (HRQL) in long-term survivors (LTS) of colorectal cancer (CRC). METHODS: Long-term CRC survivors (≥5 years) treated in previous National Surgical Adjuvant Breast and Bowel Project trials were recruited from 60 sites. After obtaining consent, a telephone survey was administered, which included HRQL instruments to measure physical health (Instrumental Activities of Daily Living [IADL], SF-12 Physical Component Scale [PCS], SF-36 Vitality Scale), mental health (SF-12 Mental Component Scale [MCS], Life Orientation Test, and Impact of Cancer), and clinical symptoms (Fatigue Symptom Inventory [FSI], European Organization for Research and Treatment of Cancer Colorectal Module [EORTC-CR38], and Brief Pain Inventory)...
February 2017: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/27272823/once-daily-accelerated-partial-breast-irradiation-preliminary-results-with-helical-tomotherapy%C3%A2
#20
Ugo DE Paula, Rolando M D'Angelillo, Raffaele Barbara, Cristina Caruso, Sara Gomellini, Aurelia Caccavari, Leopoldo Costarelli, Paola Scavina, Maria Mauri, Elena Santini, Adriana Antonaci, Francesco Cavaliere, Massimo LA Pinta, Andrea Loreti, Lucio Fortunato
BACKGROUND: Accelerated partial breast irradiation (APBI) is becoming an option for patients with low-risk breast cancer. The current practice is 38.5 Gy in 10 fractions b.i.d. over 5 days. This fractionation has a higher bioequivalent dose compared to the standard schedule. We report on preliminary results of once-daily APBI in patients treated with TomoTherapy®. PATIENTS AND METHODS: Patients with unifocal-breast disease who underwent breast-conserving surgery were enrolled in the study...
June 2016: Anticancer Research
keyword
keyword
73971
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"